TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12653410

Group type: EXPERIMENTAL
Intervention: Higher withdrawal intercepts, positive linear slopes, and greater volatility during abstinence.
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Cigarette coefficients indicating smoking-induced withdrawal reduction.
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Withdrawal patterns during abstinence.
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Severity of withdrawal during abstinence.
Number of subjects: 893
Study: 10916100

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 92

Group type: COMPARATOR
Intervention: Losartan and Enalapril (both groups)
Number of subjects: 92
Study: 8961578

Group type: EXPERIMENTAL
Intervention: Digital planimetry
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Kundin Wound Gauge
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healing Scale
Number of subjects: 82

Group type: COMPARATOR
Intervention: Johnson Scale
Number of subjects: 82

Group type: COMPARATOR
Intervention: Stereophotogrammetry
Number of subjects: 82
Study: 1325762

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen with 2.5 mg of micronized medroxyprogesterone acetate daily continuously (group C-2.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen and 5.0 mg of micronized medroxyprogesterone acetate daily continuously (group C-5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogen on days 1 through 25 and 5 mg of micronized medroxyprogesterone acetate on days 14 through 25 (group S-5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (C-2.5, C-5, S-5)
Number of subjects: 0
Study: 6363096

Group type: EXPERIMENTAL
Intervention: 400 mg once daily metoprolol Durules
Number of subjects: 27

Group type: COMPARATOR
Intervention: 200 mg metoprolol and 25 mg hydrochlorothiazide (Selokomb)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Change from double dose of metoprolol Durules to combination therapy
Number of subjects: 27
Study: 30885955

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg daily for 8 weeks
Number of subjects: 32
Study: 30025009

Group type: EXPERIMENTAL
Intervention: Subcrestal implants (1 mm subcrestally placed)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Crestal implants (placed at the bone crest level)
Number of subjects: 54
Study: 26655606

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 25281042

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 21519291

Group type: EXPERIMENTAL
Intervention: ACU-4429 (2 mg to 75 mg)
Number of subjects: 0
Study: 21253373

Group type: EXPERIMENTAL
Intervention: propofol/remifentanil (PRO/REM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: sevoflurane/remifentanil (SEV/REM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: desflurane/remifentanil (DES/REM)
Number of subjects: 60
Study: 17439908

Group type: EXPERIMENTAL
Intervention: Interferon‐beta1a (IFN‐beta1a), 22 mug subcutaneously weekly
Number of subjects: 345

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: SPMS patients
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Increased fatigue, EDSS and Arm Index scores
Number of subjects: 345
Study: 15729227

Group type: EXPERIMENTAL
Intervention: Intensive training with compactEASIE simulator (3 sessions over 7 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard clinical training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intensive simulator/clinical training
Number of subjects: 37
Study: 11904789

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (standard pharmacological antiemetic treatment: metoclopramide and dexamethasone i.v.)
Number of subjects: 71
Study: 9651908

Group type: EXPERIMENTAL
Intervention: Menopausal symptoms (presence of hot flashes, irregular menstrual cycles)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Irregular menstrual cycles
Number of subjects: 290

Group type: COMPARATOR
Intervention: Asymptomatic women
Number of subjects: 290
Study: 8919261

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2774036

Group type: EXPERIMENTAL
Intervention: Flurbiprofen sodium 0.03%
Number of subjects: 139

Group type: COMPARATOR
Intervention: No flurbiprofen (Control)
Number of subjects: 139
Study: 889379

Group type: EXPERIMENTAL
Intervention: Bacteria Controlled Nursing Unit (BCNU)
Number of subjects: 0
Study: 29524454

Group type: EXPERIMENTAL
Intervention: Vamorolone (0.1-20.0 mg/kg single doses; 1.0-20 mg/kg/day for 14 days)
Number of subjects: 86
Study: 28279757

Group type: EXPERIMENTAL
Intervention: Hohl manipulator
Number of subjects: 91

Group type: COMPARATOR
Intervention: Colpo-Probe manipulator
Number of subjects: 91
Study: 25786050

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise programme (24 twice-weekly sessions of combined aerobic, muscle strength training exercises and education)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise programme
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study: 23924790

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg + GVAX
Number of subjects: 30
Study: 21133742

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Propofol/Ketamine (P/K)
Number of subjects: 28
Study: 19149323

Group type: EXPERIMENTAL
Intervention: Cognitive-rehabilitation and problem-solving therapy intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study: 15673100

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate-electrolyte (CHO-E) solution
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carbohydrate-free placebo (P)
Number of subjects: 9
Study: 11895067

Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage-colony stimulating factor (GM-CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9620134

Group type: EXPERIMENTAL
Intervention: Doppler waveform analysis alone
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Doppler waveform analysis plus ABI
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Doppler waveform analysis plus SEGP data
Number of subjects: 81
Study: 8560525

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Paracetamol (15 mg/kg)
Number of subjects: 16
Study: 2462069

Group type: EXPERIMENTAL
Intervention: Sodium etidronate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 1245792

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDC), 750 mg per day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB), 90 or 180 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combination of CDC and PB
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31787150

Group type: EXPERIMENTAL
Intervention: Six-month individualized, progressive, multicomponent physical exercise program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Routine activities (Control)
Number of subjects: 112
Study: 30796143

Group type: EXPERIMENTAL
Intervention: 12-week regimen of doxycycline or clarithromycin/hydroxychloroquine after a 2-week open-label regimen of intravenous ceftriaxone
Number of subjects: 239

Group type: COMPARATOR
Intervention: 2-week regimen of intravenous ceftriaxone
Number of subjects: 239
Study: 28698186

Group type: EXPERIMENTAL
Intervention: Fasting serum insulin levels
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Fourth quartile of insulin
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: HOMA‐IR
Number of subjects: 591

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 591

Group type: COMPARATOR
Intervention: Insulin:glucose molar ratio
Number of subjects: 591
Study: 25241271

Group type: EXPERIMENTAL
Intervention: Increase in diastolic blood pressure ≥15 mmHg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Baseline diastolic blood pressure of ≥80 mmHg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Systolic and diastolic blood pressures at pregnancy week 12
Number of subjects: 209
Study: 23404232

Group type: EXPERIMENTAL
Intervention: Regadenoson at peak exercise
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard regadenoson injection at rest
Number of subjects: 200
Study: 21827166

Group type: EXPERIMENTAL
Intervention: SODIS (solar disinfection of drinking water)
Number of subjects: 928

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 928
Study: 19839214

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17144782

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angioplasty and stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 0
Study: 15075878

Group type: EXPERIMENTAL
Intervention: Pterygium surgery using bare sclera technique combined with intraoperative mitomycin C
Number of subjects: 54
Study: 11207992

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 671

Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 671
Study: 9394313

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 130
Study: 7614283

Group type: EXPERIMENTAL
Intervention: Proparacaine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tetracaine
Number of subjects: 23
Study: 2953501

Group type: EXPERIMENTAL
Intervention: Sufentanil bolus 0.1 microgram X kg‐1 followed by continuous sufentanil infusion of 0‐7 micrograms X min‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl bolus 0.7 microgram X kg‐1 followed by continuous fentanyl infusion of 0‐50 micrograms X min‐1
Number of subjects: 50
Study: 29655134

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention (UC + 4 weeks of small, abstinence contingent financial incentives)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual Care (UC) including pharmacotherapy and counseling sessions
Number of subjects: 139
Study: 27737692

Group type: EXPERIMENTAL
Intervention: Responders to PSA testing invitation
Number of subjects: 197763

Group type: COMPARATOR
Intervention: Nonresponders to PSA testing invitation
Number of subjects: 197763
Study: 25675682

Group type: EXPERIMENTAL
Intervention: Baby EAR
Number of subjects: 20

Group type: COMPARATOR
Intervention: JR
Number of subjects: 20
Study: 23497109

Group type: EXPERIMENTAL
Intervention: Telemonitoring system (non-invasive system monitoring vital signs including oxygen saturation, heart rate, near-body temperature, overall physical activity)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Telemonitoring system
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 99
Study: 20825622

Group type: EXPERIMENTAL
Intervention: Short waiting time (SWT ≤ 3 months)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Nonfixed waiting time (NFWT > 3 months)
Number of subjects: 438
Study: 18300748

Group type: EXPERIMENTAL
Intervention: SIRIUS eligible group (n=296)
Number of subjects: 838

Group type: COMPARATOR
Intervention: SIRIUS ineligible group (n=542)
Number of subjects: 838
Study: 15142001

Group type: EXPERIMENTAL
Intervention: Combination of creatine (20 g per day for 6 days) and sodium bicarbonate (0.3 g per kg body weight 2 hours before swims)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of creatine and sodium bicarbonate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11676942

Group type: EXPERIMENTAL
Intervention: Rescue PCI (TIMI 0 or 1 flow at 90 minutes)
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Adjunctive PCI (TIMI 2 or 3 flow at 90 minutes)
Number of subjects: 1938

Group type: EXPERIMENTAL
Intervention: Delayed PCI (performed >150 minutes after symptom onset)
Number of subjects: 1938

Group type: COMPARATOR
Intervention: Successful thrombolysis (TIMI 3 flow at 90 minutes) without revascularization
Number of subjects: 1938
Study: 9570429

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) tablet
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) spray
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) spray
Number of subjects: 205
Study: 7932931

Group type: EXPERIMENTAL
Intervention: Oropharyngeal suction followed by tracheal suction
Number of subjects: 49

Group type: COMPARATOR
Intervention: Oropharyngeal suction
Number of subjects: 49
Study: 2438638

Group type: EXPERIMENTAL
Intervention: IM or oral iron treatments
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 191
Study: 30322357

Group type: EXPERIMENTAL
Intervention: Interarytenoid assessment protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison with operating surgeon
Number of subjects: 30
Study: 29174940

Group type: EXPERIMENTAL
Intervention: Prostate-rectum hydrogel spacer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no spacer)
Number of subjects: 0
Study: 26701964

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 25176223

Group type: EXPERIMENTAL
Intervention: Myocet (M) 60 mg/m2 i.v. plus cyclophosphamide (C) 600 mg/m2 on Day 1 of a 21‐day cycle (Arm A)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Myocet (M) 50 mg/m2 plus vinorelbine (V) 25 mg/m2 i.v. on Day 1 and V 60 mg/m2 orally on Day 8 on a 21‐day cycle (Arm B)
Number of subjects: 233
Study: 23174844

Group type: EXPERIMENTAL
Intervention: Needles
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Seeds
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 21163010

Group type: EXPERIMENTAL
Intervention: Dual anti-collagen membranes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atelocollagen membranes
Number of subjects: 24
Study: 17426001

Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia combined with postoperative epidural analgesia
Number of subjects: 66

Group type: COMPARATOR
Intervention: Postoperative epidural analgesia alone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Postoperative intravenous analgesia
Number of subjects: 66
Study: 16279895

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 2 mg/kg body weight of Photosan-3, light activation performed 48 hours after intravenous application
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group treated with endoprostheses, no PDT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 11280104

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonselective NSAIDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: NSAIDs with concomitant GPAs
Number of subjects: 0
Study: 9208360

Group type: EXPERIMENTAL
Intervention: Generic verapamil (120 mg twice daily for 14 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Brand-name verapamil (120 mg twice daily for 14 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Generic verapamil
Number of subjects: 8

Group type: COMPARATOR
Intervention: Brand-name verapamil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both verapamil products
Number of subjects: 8
Study: 7525541

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study: 3678219

Group type: EXPERIMENTAL
Intervention: Gp I (n = 22) with rest intervals of 5, 15, 45, 135, 405, and 1215 seconds
Number of subjects: 39

Group type: COMPARATOR
Intervention: Gp II (n = 17) with rest intervals of 10, 30, 90, 270, 810, and 2550 seconds
Number of subjects: 39
Study: 31990936

Group type: EXPERIMENTAL
Intervention: Anagliptin (200 mg twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (previous treatment schedules)
Number of subjects: 24
Study: 30961415

Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan radioimmunotherapy (Y90)
Number of subjects: 46
Study: 27096722

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250‐μg metered‐dose inhaler
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline placebo metered‐dose inhaler
Number of subjects: 22
Study: 24996569

Group type: EXPERIMENTAL
Intervention: Gadofosveset
Number of subjects: 11

Group type: COMPARATOR
Intervention: Gadobenate dimeglumine
Number of subjects: 11
Study: 24196464

Group type: EXPERIMENTAL
Intervention: One-to-one therapy
Number of subjects: 249

Group type: COMPARATOR
Intervention: Group-based therapy
Number of subjects: 249

Group type: COMPARATOR
Intervention: Monitored home program
Number of subjects: 249
Study: 21703806

Group type: EXPERIMENTAL
Intervention: CABG with previous or simultaneous carotid endarterectomy (CEA)
Number of subjects: 185

Group type: COMPARATOR
Intervention: CABG followed by carotid endarterectomy (CEA)
Number of subjects: 185
Study: 19506003

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation with controlled breathing (6 breaths/min for 10 minutes twice daily during the eight-week treatment period)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation
Number of subjects: 44
Study: 16400508

Group type: EXPERIMENTAL
Intervention: Comprehensive Health Enhancement Support System (CHESS)
Number of subjects: 8
Study: 15277159

Group type: EXPERIMENTAL
Intervention: High zinc intake (12 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low zinc intake (4 mg/d)
Number of subjects: 16
Study: 10930963

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 1600 microg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 microg twice daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: BUD and FP (comparison)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BUD
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FP
Number of subjects: 9
Study: 9024229

Group type: EXPERIMENTAL
Intervention: recombinant DNA‐derived preparations of human GH
Number of subjects: 121
Study: 8070986

Group type: EXPERIMENTAL
Intervention: Non-contact Therapeutic Touch (NCTT)
Number of subjects: 0
Study: 30782712

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention (one treatment for five consecutive weeks)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (treatment offered after 6 weeks)
Number of subjects: 70
Study: 29641571

Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10 supplementation for four years
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 27001965

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 2573

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2573
Study: 25216762

Group type: EXPERIMENTAL
Intervention: Lapatinib and capecitabine (L-CAP)
Number of subjects: 197
Study: 22753087

Group type: EXPERIMENTAL
Intervention: Omega 3/6 supplementation (Equazen eye q)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 19921305

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT), 10 sessions
Number of subjects: 21

Group type: COMPARATOR
Intervention: Waiting list (control group), 12-week waiting period
Number of subjects: 21
Study: 18844819

Group type: EXPERIMENTAL
Intervention: Sleep therapy (multi-component intervention including sleep restriction, cognitive behavioral therapy, bright-light therapy, structured physical activity, and body temperature manipulations)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waiting-list control group (healthy well-sleeping age-matched subjects)
Number of subjects: 38
Study: 16192592

Group type: EXPERIMENTAL
Intervention: classical CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: ECS present
Number of subjects: 1475

Group type: COMPARATOR
Intervention: ECS absent
Number of subjects: 1475
Study: 12874586

Group type: EXPERIMENTAL
Intervention: Gelatine-coated Dacron (GEL-D) grafts
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Collagen-coated Dacron (COL-D) grafts
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Stretch PTFE grafts
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study: 10583440

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (30 ppm, 30 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control gas
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aspirin (640 mg x 1 orally)
Number of subjects: 15
Study: 8913542

Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan 100 mg (multiple dosing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (multiple dosing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan (all doses)
Number of subjects: 0
Study: 1649497

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens (CEE)
Number of subjects: 40
Study: 6613808

Group type: EXPERIMENTAL
Intervention: Verapamil, 320 mg per day
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31542766

Group type: EXPERIMENTAL
Intervention: Educational leaflet on seat belt use
Number of subjects: 2216

Group type: COMPARATOR
Intervention: Control group (no educational leaflet)
Number of subjects: 2216
Study: 27364640

Group type: EXPERIMENTAL
Intervention: 2.5-year screening interval
Number of subjects: 7915
Study: 26866518

Group type: EXPERIMENTAL
Intervention: Secukinumab (300, 150 mg)
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1144